Related references
Note: Only part of the references are listed.Efficacy of favipiravir in adults with mild COVID-19: a randomized, double-blind, multicentre, placebo-controlled clinical trial
Mohammad Bosaeed et al.
CLINICAL MICROBIOLOGY AND INFECTION (2022)
Effectiveness of Favipiravir on Nonsevere, Early-Stage COVID-19 in Japan: A Large Observational Study Using the COVID-19 Registry Japan
Shinya Tsuzuki et al.
INFECTIOUS DISEASES AND THERAPY (2022)
Evaluation of the representativeness of data in the COVID-19 Registry Japan during the first six waves of the epidemic
Kayoko Hayakawa et al.
GLOBAL HEALTH & MEDICINE (2022)
AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial
Andrey A. Ivashchenko et al.
CLINICAL INFECTIOUS DISEASES (2021)
Clinical Epidemiology of Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) in Japan: Report of the COVID-19 Registry Japan
Nobuaki Matsunaga et al.
CLINICAL INFECTIOUS DISEASES (2021)
COVID-19 treatment options: a difficult journey between failed attempts and experimental drugs
Alessandra Bartoli et al.
INTERNAL AND EMERGENCY MEDICINE (2021)
Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial
Zarir F. Udwadia et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2021)
A multicenter non-randomized, uncontrolled single arm trial for evaluation of the efficacy and the safety of the treatment with favipiravir for patients with severe fever with thrombocytopenia syndrome
Koichiro Suemori et al.
PLOS NEGLECTED TROPICAL DISEASES (2021)
Efficacy and Safety of Favipiravir in Moderate COVID-19 Pneumonia Patients without Oxygen Therapy: A Randomized, Phase III Clinical Trial
Masaharu Shinkai et al.
INFECTIOUS DISEASES AND THERAPY (2021)
A nationwide questionnaire survey of clinic doctors on antimicrobial stewardship in Japan
Yoshiaki Gu et al.
JOURNAL OF INFECTION AND CHEMOTHERAPY (2020)
A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19
Yohei Doi et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase
Yousuke Furuta et al.
PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES (2017)